NDI-010976
- Catalog NO.:A858139
- CAS No. : 1434635-54-7
- Molecular Formula:C28H31N3O8S
- Molecular Weight: 569.63
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 1434635-54-7 | Appearance | White solid |
Catalog Number | A858139 | MDL Number | MFCD28963986 |
Molecular Formula | C28H31N3O8S | Molecular Weight | 569.63 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | (R)-2-(1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol-2-yl)-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-2-methylpropanoicacid | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H335 | Class | |
Precautionary Statements | P280-P305+P351+P338 | Packing Group |
Description
ND-630, also known as GS-0976, NDI-010976, and firsocostat, is a potent ACC inhibitor. ND-630 nteracts within the ACC phosphopeptide acceptor and dimerization site to prevent dimerization and inhibit the enzymatic activity of both ACC isozymes, reduce fatty acid synthesis and stimulate fatty acid oxidation in cultured cells and in animals, and exhibit favorable drug-like properties. ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. When administered chronically to Zucker diabetic fatty rats, ND-630 reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c (0.9% reduction). |